HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens

Guidelines advocate the treatment of HCV in all HIV/HCV co-infected individuals. The aim of this randomized, open-label study (ClinicalTrials.gov identifier: NCT02707601; https://clinicaltrials.gov/ct2/show/NCT02707601) was to evaluate the safety/efficacy of ledipasvir/sofosbuvir (LDV/SOF) co-admini...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2020-01, Vol.15 (1), p.e0224875-e0224875
Hauptverfasser:	Huhn, Gregory D, Ramgopal, Moti, Jain, Mamta K, Hinestrosa, Federico, Asmuth, David M, Slim, Jihad, Goldstein, Deborah, Applin, Shauna, Ryu, Julie H, Jiang, Shuping, Cox, Stephanie, Das, Moupali, Nguyen-Cleary, Thai, Piontkowsky, David, Guyer, Bill, Rossaro, Lorenzo, Haubrich, Richard H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - administration & dosage Adenine - analogs & derivatives Adult Aged Alanine Anti-HIV agents Antimicrobial agents Antiretroviral agents Antiretroviral drugs Antiviral drugs Benzimidazoles - administration & dosage Biological products industry Biology and Life Sciences Boceprevir Cirrhosis Cobicistat Coinfection - drug therapy Coinfection - virology Confidence intervals Drug Combinations Drug Resistance, Viral - drug effects Drug therapy Elvitegravir Emtricitabine Emtricitabine - administration & dosage Female Fluorenes - administration & dosage Genotypes Hepacivirus - pathogenicity Hepatitis C - complications Hepatitis C - drug therapy Hepatitis C - virology Hepatitis C virus HIV HIV Infections - complications HIV Infections - drug therapy HIV Infections - virology HIV-1 - drug effects HIV-1 - pathogenicity Human immunodeficiency virus Humans Hypercholesterolemia Infections Labels Liver cirrhosis Liver diseases Male Medicine and Health Sciences Middle Aged Pharmaceutical industry Plasma Protease inhibitors Randomization Ribonucleic acid Rilpivirine RNA RNA, Viral - isolation & purification Simeprevir Sofosbuvir - administration & dosage Studies Telaprevir Tenofovir Tenofovir - administration & dosage Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Guidelines advocate the treatment of HCV in all HIV/HCV co-infected individuals. The aim of this randomized, open-label study (ClinicalTrials.gov identifier: NCT02707601; https://clinicaltrials.gov/ct2/show/NCT02707601) was to evaluate the safety/efficacy of ledipasvir/sofosbuvir (LDV/SOF) co-administered with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or rilpivirine/F/TAF (R/F/TAF) in HIV-1/HCV co-infected participants. Participants with HIV-1 RNA
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0224875